Lumevoq demonstrated continued vision improvement in Leber hereditary optic neuropathy 4 years after a single gene therapy injection, according to a press release from GenSight Biologics.
Participants with Leber hereditary optic neuropathy (LHON) experienced a mean improvement of 22.5 letters of best corrected visual acuity in the study eye that received Lumevoq (GS010; lenadogene nolparvovec) at 4 years compared with their lowest point, while sham-treated eyes experienced an improvement of 20.5 letters, according to the release. Results come from RESTORE, a long-term follow-up study